TMS Co.,Ltd. enters into exclusive negotiation agreement with a European company for malignant brain tumors

ティムス has entered into an exclusive negotiation agreement with European company TME Pharma A.G. for NOX-A12 targeting brain tumors.

Full text unavailableWorking from the headline and excerpt

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

ティムス has entered into an exclusive negotiation agreement with TME Pharma A.G. for NOX-A12 targeting brain tumors.

At a glance

Customerティムス and TME Pharma A.G. enter into an exclusive negotiation agreement

Target conditionDevelopment of NOX-A12 for malignant brain tumors

Drug nameNOX-A12（olaptesed）

Agreement typeExclusive negotiation agreement

Reference information. Every claim resolves to something the story actually named.

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

news.nicovideo.jpNews

AgreesOpen

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.

TMS Co.,Ltd. enters into exclusive negotiation agreement with a European company for malignant brain tumors | News